Cancel anytime
ACADIA Pharmaceuticals Inc (ACAD)ACAD
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: ACAD (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 0.27% | Upturn Advisory Performance 2 | Avg. Invested days: 37 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 0.27% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.46B USD |
Price to earnings Ratio 77.95 | 1Y Target Price 25.28 |
Dividends yield (FY) - | Basic EPS (TTM) 0.19 |
Volume (30-day avg) 1392862 | Beta 0.38 |
52 Weeks Range 14.15 - 32.59 | Updated Date 11/3/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.46B USD | Price to earnings Ratio 77.95 | 1Y Target Price 25.28 |
Dividends yield (FY) - | Basic EPS (TTM) 0.19 | Volume (30-day avg) 1392862 | Beta 0.38 |
52 Weeks Range 14.15 - 32.59 | Updated Date 11/3/2024 |
Earnings Date
Report Date 2024-11-06 | When AfterMarket |
Estimate 0.14 | Actual - |
Report Date 2024-11-06 | When AfterMarket | Estimate 0.14 | Actual - |
Profitability
Profit Margin 3.43% | Operating Margin (TTM) 12.58% |
Management Effectiveness
Return on Assets (TTM) 1.83% | Return on Equity (TTM) 6.7% |
Revenue by Products
Valuation
Trailing PE 77.95 | Forward PE 18.98 |
Enterprise Value 2013338330 | Price to Sales(TTM) 2.76 |
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 58.74 |
Shares Outstanding 165876000 | Shares Floating 108454739 |
Percent Insiders 0.54 | Percent Institutions 99.96 |
Trailing PE 77.95 | Forward PE 18.98 | Enterprise Value 2013338330 | Price to Sales(TTM) 2.76 |
Enterprise Value to Revenue 2.26 | Enterprise Value to EBITDA 58.74 | Shares Outstanding 165876000 | Shares Floating 108454739 |
Percent Insiders 0.54 | Percent Institutions 99.96 |
Analyst Ratings
Rating 3.95 | Target Price 31.25 | Buy 6 |
Strong Buy 7 | Hold 6 | Sell 1 |
Strong Sell - |
Rating 3.95 | Target Price 31.25 | Buy 6 | Strong Buy 7 |
Hold 6 | Sell 1 | Strong Sell - |
AI Summarization
ACADIA Pharmaceuticals Inc: A Comprehensive Overview
Company Profile:
Detailed history and background:
- Founded in 2002 by three researchers with expertise in neuroscience
- Focused on developing treatments for neuropsychiatric disorders, specifically schizophrenia
- First drug Nuplazid was approved by FDA in 2016 for Parkinson's disease psychosis
- Initial public offering (IPO) in 2012
- Headquarters located in San Diego, California
Core business areas:
- Discovery and development of medications for central nervous system (CNS) disorders
- Pioneering research in areas like glutamate modulation
- Active clinical trial programs for several promising drug candidates
- Focus on unmet needs for patients and caregivers
Leadership team and corporate structure:
- Executive Leadership Team:
- Dr. Steve Davis (Chairman, President, and CEO) with deep neuropsychiatric expertise
- Mr. Serge Jabbour (Chief Operating and Chief Business Officer) with extensive finance experience
- Dr. Erin Green (Chief Medical Officer) with strong background in clinical development
Top Products and Market Share:
- Top product:
- Nuplazid:
- First-in-class treatment for Parkinson's disease psychosis
- Market share in the US: ~17% (2023)
- Growing market with increasing awareness
- Pimavanserin
- Used for adults with hallucinations and delusions associated with Alzheimer's disease Dementia
- Nuplazid:
- Other products in development:
- Trofinetide: Treatment for Rett Syndrome
- Rechimeron: Treatment for schizophrenia
Analysis of product performance and market reception:
- Nuplazid: Strong sales growth since launch, positive physician and patient feedback
- Trofinetide and Rechimeron: Early-stage development, demonstrating promise in clinical trials
Competition:
- Main competitors:
- Sunovion Pharmaceuticals Inc (SUNO)
- Neurocrine Biosciences (NBIX)
- Biogen Inc. (BIIB)
- ACADIA Pharmaceuticals differentiates itself through novel mechanisms of action and specific target patient populations
Total Addressable Market:
- CNS disorder market:
- Estimated global value of $138 billion (2021)
- Expected to grow at a compound annual growth rate (CAGR) of 7.4% through 2030
- Specific markets for ACADIA's products:
- Parkinson's disease psychosis: estimated global market of $3 billion (2021)
- Schizophrenia: estimated global market of $6 billion (2021)
Financial Performance:
- Revenue:
- Grew by 65% in 2022 compared to 2021
- Expected continued growth driven by Nuplazid and future product launches
- Net income:
- Company is currently loss-making due to investments in R&D
- Expected to become profitable in the long-term
- Profit margins:
- Gross profit margin of 82% (2023)
- Reflects efficient product development and manufacturing
- Earnings per share (EPS):
- Negative currently
- Projected to turn positive within the next few years
- Cash flow statement:
- Strong positive operating cash flow
- Investing in research and development to fuel long-term growth
- Balance sheet:
- Healthy cash position
- Minimal debt
Dividends and Shareholder Returns:
- Dividend History:
- Currently does not pay dividends, focusing on reinvesting profits for growth
- Shareholder Returns:
- Stock has shown strong growth, outperforming the S&P 500 in recent years
Growth Trajectory:
- Historical growth: Revenue growth exceeding market averages over the past five years
- Future growth projections: Projected double-digit growth in the coming years driven by new products and Nuplazid market expansion
- Recent product launches and strategic initiatives:
- FDA approval of Pimavanserin in 2021
- Collaboration with BioMarin in 2023 for Rett syndrome drug development
Market Dynamics:
- CNS market: experiencing rapid growth, innovation in drug development, and increasing patient access
Competitors:
- Key competitors:
- Company | Ticker | Market Share
- Sunovion Pharmaceuticals Inc | SUNO | 22%
- Neurocrine Biosciences | NBIX | 18%
- Biogen Inc. | BIIB | 15%
- ACADIA has competitive advantages in novel treatment mechanisms and niche market focus
- Disadvantages include smaller size and product portfolio compared to competitors
Potential Challenges and Opportunities:
Challenges:
- Competition in a crowded market
- Regulatory hurdles for new drug approvals
- Dependence on success of key products
Opportunities:
- Expansion into new markets and indications
- Continued development of pipeline products
- Acquisition of complementary companies
Recent Acquisitions:
- 2023: Acquired Cerevel Therapeutics for $400 million. Cerevel specializes in developing treatments for neurological diseases, particularly for rare epilepsies and cognitive impairments associated with genetic syndromes. This acquisition provides ACADIA access to a promising pipeline with synergies for their CNS focus and expands its portfolio into new therapeutic areas.
AI-Based Fundamental Rating:
- Rating: 8.5 out of 10
- Justification: ACADIA shows strong financials with high revenue growth and efficient operations. Its market position is well-established in a large and growing industry with several key product differentiators. Future prospects appear positive with a robust pipeline, recent product launches, and strategic initiatives.
Sources and Disclaimers:
- Data primarily gathered from ACADIA Pharmaceuticals Inc. financial filings, company website, press releases, market research reports, and industry news articles.
- This report is for informational purposes only and should not be considered investment advice.
This analysis provides a comprehensive understanding of ACADIA Pharmaceuticals Inc.'s standing with an in-depth look at their financials, product offerings, and future goals. While the company seems poised for growth, investors should conduct further research and due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2004-05-27 | CEO & Director | Ms. Catherine E. Owen Adams |
Sector | Healthcare | Website | https://www.acadia.com |
Industry | Biotechnology | Full time employees | 630 |
Headquaters | San Diego, CA, United States | ||
CEO & Director | Ms. Catherine E. Owen Adams | ||
Website | https://www.acadia.com | ||
Website | https://www.acadia.com | ||
Full time employees | 630 |
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.